LSTA Lisata Therapeutics Inc.: Earnings per one share for the last 12 months

Official company branding of Lisata Therapeutics Inc. (LSTA)

Lisata Therapeutics (LSTA) develops systems for the deep penetration of drugs into tumor tissues. The current EPS YoY TTM trajectory illustrates that success depends on the CendR platform and pancreatic cancer trials, where the parameter value equals 11.30. The company's innovations alter the neoplastic environment, rendering tumors vulnerable. Currently, there is no revenue, and potential income is tied to future contracts with pharmaceutical industry behemoths.

Lisata Therapeutics (LSTA) - Net earnings per share (EPS TTM) from 02/11/2024 to 11/17/2026

Lisata Therapeutics - analytical breakdowns and key metrics (LSTA)

Initial company analysis:LSTA, Lisata
Manufactured products of Lisata

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period, allowing investors to filter out short-term noise and identify the true trajectory of profitability. By analyzing the current EPS YoY TTM dynamics, one can assess how the optimization of complex medical logistics for chemotherapy drugs converts into financial results for Lisata Therapeutics (LSTA), preventing the unjustified freezing of investment capital.